Gilead Sciences Developing HIV Treatment Meets Its Goal in Phase II Clinical Trial
FOSTER CITY, Calif.-- Biopharmaceutical company Gilead Sciences Inc. said its developing HIV treatment GS-9137 met its goal in a midstage study.
The drug candidate is an integrase inhibitor that aims to interfere with HIV replication by blocking the virus from integrating into cells. The Phase II clinical trial involved the drug candidate in combination with ritonavir and a background antiretroviral program. The study's goal was to at least be as effective as the comparison treatment.
The study involved 50-milligram and 125-milligram doses. The 20-milligram dose was discontinued early on in the study because of a high rate of virologic failure.
Shares of Gilead closed down 43 cents to $73.63 on the Nasdaq Stock Market.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment